Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
AIM: We aimed to investigate the efficacy of interferon and ribavirin-free sofosbuvir/ledipasvir (SOF/LDV) and ritonavir boosted paritaprevir/ombitasvir with or without dasabuvir (2D/3D) regimens in a real-life cohort of human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected patients. The study focused on efficacy, need for changes in antiretroviral therapy (ART) due to drug-drug interaction (DDI), and treatment-associated changes in liver stiffness.
METHODS: In this study 36 patients (n = 21 SOF/LDV and n = 15 2D/3D) were retrospectively analyzed. Depending on the genotype the following treatment regimens were used: HCV genotype (GT)-1: either SOF/LDV or 3D, no patient with HCV-GT2 was included, HCV-GT3: SOF/LDV, HCV-GT4: 2D.
RESULTS: Approximately one third (35.3%) of patients were treatment-experienced and 13.9% had cirrhosis. Antiretroviral therapy had to be changed in 38.1% of SOF/LDV and 60% of 2D/3D patients prior to anti-HCV treatment due to expected DDIs. We observed sustained virologic response (SVR) rates of 100% in patients treated with SOF/LDV (19/19) and 2D/3D (14/14). One 2D/3D patient was lost to follow-up, while two SOF/LDV patients died during therapy from non-treatment-related causes. They were excluded from the analysis. Between baseline and follow-up liver stiffness decreased from 11.4 to 8.3 kPa (p = 0.008) and from 8.1 to 5.7 kPa (p = 0.001) in SOF/LDV and 2D/3D patients, respectively.
CONCLUSIONS: We confirmed the excellent HCV eradication rates >95% in a real-life cohort of HIV/HCV coinfected patients treated with SOF/LDV and 2D/3D. We observed no HCV relapse or breakthrough. More patients treated with 2D/3D required a change in ART than patients treated with SOF/LDV. Additionally, HCV eradication led to a rapid decline in liver stiffness.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:129 |
|---|---|
| Enthalten in: |
Wiener klinische Wochenschrift - 129(2017), 15-16 vom: 28. Aug., Seite 517-526 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Steiner, Sebastian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.05.2019 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00508-016-1162-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM268414874 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM268414874 | ||
| 003 | DE-627 | ||
| 005 | 20231224222617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00508-016-1162-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0894.xml |
| 035 | |a (DE-627)NLM268414874 | ||
| 035 | |a (NLM)28130599 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Steiner, Sebastian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.05.2019 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: We aimed to investigate the efficacy of interferon and ribavirin-free sofosbuvir/ledipasvir (SOF/LDV) and ritonavir boosted paritaprevir/ombitasvir with or without dasabuvir (2D/3D) regimens in a real-life cohort of human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected patients. The study focused on efficacy, need for changes in antiretroviral therapy (ART) due to drug-drug interaction (DDI), and treatment-associated changes in liver stiffness | ||
| 520 | |a METHODS: In this study 36 patients (n = 21 SOF/LDV and n = 15 2D/3D) were retrospectively analyzed. Depending on the genotype the following treatment regimens were used: HCV genotype (GT)-1: either SOF/LDV or 3D, no patient with HCV-GT2 was included, HCV-GT3: SOF/LDV, HCV-GT4: 2D | ||
| 520 | |a RESULTS: Approximately one third (35.3%) of patients were treatment-experienced and 13.9% had cirrhosis. Antiretroviral therapy had to be changed in 38.1% of SOF/LDV and 60% of 2D/3D patients prior to anti-HCV treatment due to expected DDIs. We observed sustained virologic response (SVR) rates of 100% in patients treated with SOF/LDV (19/19) and 2D/3D (14/14). One 2D/3D patient was lost to follow-up, while two SOF/LDV patients died during therapy from non-treatment-related causes. They were excluded from the analysis. Between baseline and follow-up liver stiffness decreased from 11.4 to 8.3 kPa (p = 0.008) and from 8.1 to 5.7 kPa (p = 0.001) in SOF/LDV and 2D/3D patients, respectively | ||
| 520 | |a CONCLUSIONS: We confirmed the excellent HCV eradication rates >95% in a real-life cohort of HIV/HCV coinfected patients treated with SOF/LDV and 2D/3D. We observed no HCV relapse or breakthrough. More patients treated with 2D/3D required a change in ART than patients treated with SOF/LDV. Additionally, HCV eradication led to a rapid decline in liver stiffness | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 3D | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Hepatitis C virus | |
| 650 | 4 | |a Ledipasvir | |
| 650 | 4 | |a Sofosbuvir | |
| 650 | 7 | |a Anilides |2 NLM | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Benzimidazoles |2 NLM | |
| 650 | 7 | |a Carbamates |2 NLM | |
| 650 | 7 | |a Cyclopropanes |2 NLM | |
| 650 | 7 | |a Fluorenes |2 NLM | |
| 650 | 7 | |a Lactams, Macrocyclic |2 NLM | |
| 650 | 7 | |a Macrocyclic Compounds |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a ledipasvir, sofosbuvir drug combination |2 NLM | |
| 650 | 7 | |a ombitasvir |2 NLM | |
| 650 | 7 | |a 2302768XJ8 |2 NLM | |
| 650 | 7 | |a Uracil |2 NLM | |
| 650 | 7 | |a 56HH86ZVCT |2 NLM | |
| 650 | 7 | |a Proline |2 NLM | |
| 650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
| 650 | 7 | |a 2-Naphthylamine |2 NLM | |
| 650 | 7 | |a CKR7XL41N4 |2 NLM | |
| 650 | 7 | |a dasabuvir |2 NLM | |
| 650 | 7 | |a DE54EQW8T1 |2 NLM | |
| 650 | 7 | |a Uridine Monophosphate |2 NLM | |
| 650 | 7 | |a E2OU15WN0N |2 NLM | |
| 650 | 7 | |a Valine |2 NLM | |
| 650 | 7 | |a HG18B9YRS7 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a paritaprevir |2 NLM | |
| 650 | 7 | |a OU2YM37K86 |2 NLM | |
| 650 | 7 | |a Sofosbuvir |2 NLM | |
| 650 | 7 | |a WJ6CA3ZU8B |2 NLM | |
| 700 | 1 | |a Bucsics, Theresa |e verfasserin |4 aut | |
| 700 | 1 | |a Schwabl, Philipp |e verfasserin |4 aut | |
| 700 | 1 | |a Mandorfer, Mattias |e verfasserin |4 aut | |
| 700 | 1 | |a Scheiner, Bernhard |e verfasserin |4 aut | |
| 700 | 1 | |a Aichelburg, Maximilian Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Grabmeier-Pfistershammer, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Ferenci, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Trauner, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Peck-Radosavljevic, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Reiberger, Thomas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Wiener klinische Wochenschrift |d 1946 |g 129(2017), 15-16 vom: 28. Aug., Seite 517-526 |w (DE-627)NLM000045071 |x 1613-7671 |7 nnns |
| 773 | 1 | 8 | |g volume:129 |g year:2017 |g number:15-16 |g day:28 |g month:08 |g pages:517-526 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00508-016-1162-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 129 |j 2017 |e 15-16 |b 28 |c 08 |h 517-526 | ||